Abbott stock weekly forecast: Recent rally bracketed by support at $112.91 amid consolidation risk

Traders Union
All News
Stocks
Abbott Laboratories slips 0.65% this week

Highlights

Shares of Abbott are trading at $115.88, drifting slightly lower but maintaining a bullish long-term trend.
The stock remains technically strong, holding above both short-term and long-term moving averages with strong upward momentum.
For the next five days, shares are expected to consolidate in a $113.89 to $122.3 range, with immediate support at $112.91 and resistance at $117.34.

Investor activity shifts as legal settlement and product gains shape sentiment

Abbott agreed in August 2026 to pay roughly US$670 million to resolve ongoing legal claims tied to its preterm infant formulas, according to Yahoo Finance and multiple financial news sources. The company also reported stronger-than-expected fiscal Q2 results and raised annual profit guidance, driven by solid demand for cancer diagnostics and medical devices, as noted by Simply Wall St News. Recent product momentum continued as MiniMed Group and Abbott began U.S. shipments of the MiniMed Flex insulin pump system featuring Abbott’s Instinct glucose sensor on August 17, 2026, according to Yahoo Finance. Institutional investors also made notable adjustments to their ABT holdings during the period, which may influence market activity in the days ahead.

Upside momentum stretched over the week as technical signals highlight overbought risk

On the daily chart, the picture remains technically strong, with price holding well above key short-term and long-term moving averages, and volatility printing 3.92% for the week. Momentum is stretched to the upside, with RSI deep in the overbought zone at 77.88 and Stochastic RSI registering 100. There is some caution warranted as strong trending moves typically face consolidation or a pullback when overbought signals cluster. Immediate support sits at $112.91 while resistance comes in near $117.34, keeping price action bracketed after a sustained move lower with a firm trend.

Consolidation bias holds next week as breakout risks persist at key levels

For the next five trading days, the expected range is $113.89 to $122.3. The probability of an increase stands at 78%, with a 22% chance of a decrease. The base case is for Abbott to hold inside this band, consolidating above support at $112.91. A bullish scenario would see price close above $117.34 and target the upper end of the forecast range. Should shares slip below $112.91, a short-term corrective phase would likely take hold.

Sholanke Dele, market strategist, sees Abbott Laboratories near $116 facing a pivotal week after its extended rally has lost steam. He notes that overbought momentum, major legal settlements, and notable institutional moves add uncertainty to the outlook, while technicals still show price holding above key averages. The expected range is $113.89 to $122.3, but crowded overbought signals and reliance on support near $112.91 warrant caution. Base case remains consolidation unless support breaks. "If price drops below $112.91 this week, I would treat any long setups with skepticism until buyers regain control."

Earlier, analysts noted that Abbott Laboratories was demonstrating short-term bullish momentum, though overbought signals suggested gains could be constrained by technical resistance. The current setup extends that analysis, with shares now elevated and momentum stretched, making support at $112.91 the key level to watch for potential consolidation or reversal in the coming sessions.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.